Pharmaceutical company Gilead Sciences has received preliminary approval from a California federal judge for a settlement amounting to $246.8 million. This comes as an outcome of claims alleging the company engaged in anti-competitive behavior linked to its HIV medications. The settlement effectively draws to a close accusations that Gilead colluded with Teva, another major pharmaceutical company, to deliberately obstruct the arrival of generic versions of its medication on the market.
The judge deemed the settlement to be a ‘reasonable’ resolution, given the risks associated with protracted litigation. It’s important to note that this decision is preliminary – a final approval is required to legally confirm and enforce the settlement agreement. This payment will benefit the direct purchasers of Gilead’s HIV medications.
To better understand the case’s intricacies, you can delve into the details via this Law360 report.